The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo (Q39678637)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 July 2010

Language	Label	Description	Also known as
English	The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo	scientific article published on 19 July 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

neovascularization

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author name string

G Merdzhanova

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

S Gout

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

M Keramidas

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

V Edmond

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

J-L Coll

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

C Brambilla

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

E Brambilla

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

S Gazzeri

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

B Eymin

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

19 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

5392-5403

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Microenvironment changes (in pH) affect VEGF alternative splicing

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Angiogenesis: an organizing principle for drug discovery?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Neuropilin-1 is a direct target of the transcription factor E2F1 during cerebral ischemia-induced neuronal death in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

E2F - at the crossroads of life and death

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.281

31 March 2020

Identifiers

10.1038/ONC.2010.281

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39678637&oldid=2203081170"